A cardiovascular drug from biotechnology company Idorsia failed to meet its main goal in an important clinical trial, sending shares in the drugmaker down by about 15% in Monday trading on the Swiss stock exchange.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,